Citation: British Journal of Cancer. 2017, 116(7), 923-929
Author: Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ
Abstract: BACKGROUND: Activating mutations in KRAS have been suggested as potential predictive and prognostic biomarkers. However, the prognostic impact of specific point mutations remains less clear. This study assessed the prognostic impact of specific KRAS mutations on survival for patients with colorectal cancer.
METHODS: Retrospective review of patients KRAS typed for advanced and recurrent colorectal cancer between 2010 and 2015 in a UK Cancer Network.
RESULTS: We evaluated the impact of KRAS genotype in 392 patients. Mutated KRAS was detected in 42.9% of tumours. KRAS mutations were more common in moderate vs well-differentiated tumours. On multivariate analysis, primary tumour T stage (HR 2.77 (1.54-4.98), P=0.001), N stage (HR 1.51 (1.01-2.26), P=0.04), curative intent surgery (HR 0.51 (0.34-0.76), P=0.001), tumour grade (HR 0.44 (0.30-0.65), P=0.001) and KRAS mutation (1.54 (1.23-2.12), P=0.005) were all predictive of overall survival. Patients with KRAS codon 12 mutations had worse overall survival (HR 1.76 (95% CI 1.27-2.43), P=0.001). Among the five most common codon 12 mutations, only p.G12C (HR 2.21 (1.15-4.25), P=0.01) and p.G12V (HR 1.69 (1.08-2.62), P=0.02) were predictive of overall survival.
CONCLUSIONS: For patients with colorectal cancer, p.G12C and p.G12V mutations in codon 12 were independently associated with worse overall survival after diagnosis.British Journal of Cancer advance online publication 16 February 2017. doi:10.1038/bjc.2017.37 www.bjcancer.com.
Link to PubMed record
Tuesday 21 February 2017
WUTH publication: Peritoneal amyloidosis with myopathy in primary systemic (AL) amyloidosis
Citation: BMJ Case Reports. 2017, Feb 10
Author: Al-Adhami A, Steiner K, Ellis S
Link to PubMed record
Author: Al-Adhami A, Steiner K, Ellis S
Link to PubMed record
Tuesday 14 February 2017
Quality Improvement at WUTH & BMJ Quality
Quality Improvement at WUTH & BMJ Quality
Are you involved in quality improvement in your department? All WUTH staff have access to BMJ Quality, a system that allows you to plan, record and publish your Quality Improvement projects. Join us for a training session on BMJ Quality led by a BMJ Trainer.
Tuesday 7th March 2017
11.45-13.00
Maternity Conference Room, APH
BMJ Quality supports and guides you using bespoke workbooks, learning modules, webinars, videos and other resources, before generating a quality improvement project report which you can submit for publication to the BMJ Quality Improvement Reports, an open access, peer reviewed journal. Whether your quality improvement project is currently just a bright idea in your head, a project that you’re just embarking on, or is finished and ready for publication, you can use BMJ Quality to support your work. To find out more and create your account please contact the McArdle Library ext. 8610.
Predoctoral Bursary for clinicians in pathology and cancer
Predoctoral Bursary for clinicians in pathology and cancer
Please see link below regarding a Predoctoral Bursary for clinicians that is being funded by The Cancer Research UK (CRUK) and the Pathological Society.
The Cancer Research UK (CRUK) and the Pathological Society promote research in pathology and cancer to foster the development of early career clinical academic researchers with a focus on the intersection between these specialties. CRUK and the Pathological Society have set up a joint funding scheme in order to fund Pathological Society members applying for Predoctoral Research Bursaries. The Bursary is awarded for a period of up to 12 months. The bursary will provide the applicant’s salary and/or research expenses up to a total value of £45,000.
Subscribe to:
Posts (Atom)